Semaglutide is a medication that belongs to the class of drugs known as glucagon-like peptide-1 receptor agonists (GLP-1RAs). It works by mimicking the action of a hormone called glucagon-like peptide-1 (GLP-1) in the body.
Ozempic is a brand name for the injectable formulation of semaglutide. Semaglutide belongs to a class of medications called glucagon-like peptide-1 receptor agonists (GLP-1RAs), which are used to treat type 2 diabetes. It helps regulate blood sugar levels by stimulating the release of insulin, reducing the production of glucose, and slowing down the emptying of the stomach.
When Semaglutide is injected, it binds to and activates GLP-1 receptors on various cells in the body, including pancreatic cells. This activation leads to several beneficial effects:
Increased insulin secretion:
Semaglutide stimulates the release of insulin from pancreatic beta cells. Insulin is a hormone that helps lower blood sugar levels by facilitating the uptake of glucose from the bloodstream into cells.
Inhibition of glucagon secretion:
Semaglutide reduces the secretion of glucagon, a hormone that raises blood sugar levels. By inhibiting glucagon release from pancreatic alpha cells, Semaglutide helps prevent excessive production of glucose in the liver.
Slowed gastric emptying:
Semaglutide slows down the emptying of food from the stomach into the small intestine. This effect helps regulate the release of glucose into the bloodstream, preventing post-meal spikes in blood sugar levels.
Increased satiety:
Semaglutide also affects the brain’s appetite centers, leading to increased feelings of fullness (satiety). This can help reduce food intake and promote weight loss.
By promoting insulin secretion, inhibiting glucagon release, slowing gastric emptying, and increasing satiety, semaglutide helps improve glycemic control (blood sugar levels) in individuals with type 2 diabetes. It is typically used in combination with diet and exercise to manage blood sugar levels and promote weight loss.
Here are some general criteria that healthcare professionals may consider when determining if someone is a good candidate for semaglutide:
Type 2 diabetes diagnosis:
Semaglutide is specifically indicated for the treatment of type 2 diabetes, so individuals with this form of diabetes are the primary candidates.
Inadequate blood sugar control:
Semaglutide is commonly prescribed when other oral antidiabetic medications have not achieved the target blood sugar levels.
Body mass index (BMI):
Semaglutide has also been approved for weight management in individuals with a BMI of 27 or higher. It may be considered for individuals with type 2 diabetes who would benefit from weight loss.
Ability to tolerate injections:
Semaglutide is administered via subcutaneous injection once a week. A good candidate should be comfortable with self-administering injections or have a support system to assist with injections.
Overall health and medical history:
A healthcare professional will consider factors such as other medical conditions, medication interactions, and potential side effects of semaglutide to determine if it is suitable for an individual’s specific situation.
Remember, the decision to prescribe semaglutide should be made by a healthcare professional who has access to your complete medical history and can evaluate your individual weight loss needs.
